4.4 Article

Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon

Journal

PEDIATRIC BLOOD & CANCER
Volume 59, Issue 5, Pages 934-938

Publisher

WILEY-BLACKWELL
DOI: 10.1002/pbc.24103

Keywords

Kasabach-Merritt; kaposiform hemangioendothlioma; propranolol; treatment; tufted angioma; vascular tumor

Funding

  1. National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS/NIH) [K23AR060274]

Ask authors/readers for more resources

Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with KasabachMerritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications. Pediatr Blood Cancer 2012; 59: 934938. (C) 2012 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available